Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 157

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections

Kim, Minyoung Kevin, Chen, Qingquan, Echterhof, Arne, Pennetzdorfer, Nina, McBride, Robert C., Banaei, Niaz, Burgener, Elizabeth B., Milla, Carlos E., Bollyky, Paul L. · 2024 · Nature Communications

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-53994-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 78

  1. Antimicrobial Resistance, C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022). · DOI · Paper page
  2. Hatfull, G. F., Dedrick, R. M. & Schooley, R. T. Phage therapy for antibiotic-resistant bacterial infections. Annu Rev. Med. 73, 197–211 (2022). · DOI · Paper page
  3. Pirnay, J. P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434–1453 (2024). · DOI · Paper page
  4. Uyttebroek, S. et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 22, e208–e220 (2022). · DOI · Paper page
  5. Schooley, R. T. et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother 61 https://doi.org/10.1128/AAC.00954-17 (2017). · DOI · Paper page
  6. Cano, E. J. et al. Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity. Clin. Infect Dis. 73, e144–e151 (2021). · doi:10.1093/cid/ciaa705
  7. Jennes, S. et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care 21, 129 (2017). · DOI · Paper page
  8. Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 19, 35–45 (2019). · DOI · Paper page
  9. Gorski, A., Borysowski, J. & Miedzybrodzki, R. Phage therapy: Towards a successful clinical trial. Antibiotics (Basel) 9, https://doi.org/10.3390/antibiotics9110827 (2020). · DOI
  10. Leitner, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 21, 427–436 (2021). · DOI · Paper page
  11. de Jonge, P. A., Nobrega, F. L., Brouns, S. J. J. & Dutilh, B. E. Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 27, 51–63 (2019). · DOI · Paper page
  12. Jorth, P. et al. Regional isolation drives bacterial diversification within cystic fibrosis lungs. Cell Host Microbe 18, 307–319 (2015). · DOI · Paper page
  13. Limoli, D. H. et al. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur J Clin. Microbiol. Infect. Dis. 35, 947–953 (2016). · DOI · Paper page
  14. Oechslin, F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses 10, https://doi.org/10.3390/v10070351 (2018). · DOI · Paper page
  15. Stokar-Avihail, A. et al. Discovery of phage determinants that confer sensitivity to bacterial immune systems. Cell 186, 1863–1876 e1816 (2023). · DOI · Paper page
  16. Egido, J. E., Costa, A. R., Aparicio-Maldonado, C., Haas, P. J. & Brouns, S. J. J. Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol. Rev. 46, https://doi.org/10.1093/femsre/fuab048 (2022). · DOI · Paper page
  17. Gelman, D. et al. Clinical phage microbiology: a suggested framework and recommendations for the in vitro matching steps of phage therapy. Lancet Microbe 2, e555–e563 (2021). · DOI
  18. Hoyland-Kroghsbo, N. M., Maerkedahl, R. B. & Svenningsen, S. L. A quorum-sensing-induced bacteriophage defense mechanism. mBio. 4, e00362–00312 (2013). · DOI · Paper page
  19. Kronheim, S. et al. A chemical defence against phage infection. Nature 564, 283–286 (2018). · DOI · Paper page
  20. Glonti, T. & Pirnay, J. P. In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success. Viruses 14, https://doi.org/10.3390/v14071490 (2022). · DOI
  21. Abedon, S. T., Danis-Wlodarczyk, K. M. & Wozniak, D. J. Phage cocktail development for bacteriophage therapy: Toward improving spectrum of activity breadth and depth. Pharmaceuticals (Basel) 14, https://doi.org/10.3390/ph14101019 (2021). · DOI · Paper page
  22. Molina, F. et al. A new pipeline for designing phage cocktails based on phage-bacteria infection networks. Front Microbiol. 12, 564532 (2021). · DOI
  23. Schmerer, M., Molineux, I. J. & Bull, J. J. Synergy as a rationale for phage therapy using phage cocktails. PeerJ 2, e590 (2014). · DOI
  24. Hall, A. R., De Vos, D., Friman, V. P., Pirnay, J. P. & Buckling, A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78, 5646–5652 (2012). · DOI · Paper page
  25. Merabishvili, M., Pirnay, J. P. & De Vos, D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 1693, 99–110 (2018). · DOI
  26. Haines, M. E. K. et al. Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria. Front Microbiol. 12, 613529 (2021). · DOI
  27. Tagliaferri, T. L., Jansen, M. & Horz, H. P. Fighting pathogenic bacteria on two fronts: Phages and antibiotics as combined strategy. Front Cell Infect. Microbiol. 9, 22 (2019). · DOI · Paper page
  28. Gu Liu, C. et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. mBio. 11, https://doi.org/10.1128/mBio.01462-20 (2020). · DOI · Paper page
  29. Lusiak-Szelachowska, M. et al. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far. J Biomed Sci. 29, 23 (2022). · DOI · Paper page
  30. Lood, C., Haas, P. J., van Noort, V. & Lavigne, R. Shopping for phages? Unpacking design rules for therapeutic phage cocktails. Curr Opin Virol 52, 236–243 (2022). · doi:10.1016/j.coviro.2021.12.011
  31. Hammerl, J. A. et al. Reduction of Campylobacter jejuni in broiler chicken by successive application of group II and group III phages. PLoS One 9, e114785 (2014). · DOI
  32. Menor-Flores, M., Vega-Rodriguez, M. A. & Molina, F. Computational design of phage cocktails based on phage-bacteria infection networks. Comput Biol. Med. 142, 105186 (2022). · doi:10.1016/j.compbiomed.2021.105186
  33. Gu, J. et al. A method for generation phage cocktail with great therapeutic potential. PLoS One 7, e31698 (2012). · DOI · Paper page
  34. Yang, Y. et al. Development of a Bacteriophage Cocktail to Constrain the Emergence of Phage-Resistant Pseudomonas aeruginosa. Front Microbiol. 11, 327 (2020). · DOI · Paper page
  35. Tanji, Y. et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol. 64, 270–274 (2004). · DOI · Paper page
  36. Gordillo Altamirano, F. L. & Barr, J. J. Unlocking the next generation of phage therapy: the key is in the receptors. Curr Opin Biotechnol 68, 115–123 (2021). · DOI
  37. Wright, R. C. T., Friman, V. P., Smith, M. C. M. & Brockhurst, M. A. Cross-resistance is modular in bacteria-phage interactions. PLoS Biol. 16, e2006057 (2018). · DOI
  38. McVay, C. S., Velasquez, M. & Fralick, J. A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51, 1934–1938 (2007). · DOI · Paper page
  39. Morales, E. et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res 12, 122 (2012). · DOI · Paper page
  40. Lee, B. Y. et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin. Microbiol. Infect. 19, 528–536 (2013). · DOI · Paper page
  41. Cady, K. C., Bondy-Denomy, J., Heussler, G. E. & Davidson, A. R. & O’Toole, G. A. The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages. J Bacteriol 194, 5728–5738 (2012). · DOI · Paper page
  42. Xie, Y., Wahab, L. & Gill, J. J. Development and validation of a microtiter plate-based assay for determination of bacteriophage host range and virulence. Viruses 10 https://doi.org/10.3390/v10040189 (2018). · DOI
  43. Dimitriu, T. et al. Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition. Cell Host Microbe 30, 31–40.e35 (2022). · DOI
  44. Ashworth, E. A. et al. Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo. Nat. Commun. 15, 1547 (2024). · DOI
  45. Chan, B. K. et al Personalized Inhaled Bacteriophage Therapy Decreases Multidrug-Resistant Pseudomonas aeruginosa. medRxiv https://doi.org/10.1101/2023.01.23.22283996 (2023). · doi:10.1101/2023.01.23.22283996
  46. Hatfull, G. F. & Hendrix, R. W. Bacteriophages and their genomes. Curr. Opin Virol 1, 298–303 (2011). · DOI · Paper page
  47. Burrows, L. L. Pseudomonas aeruginosa twitching motility: type IV pili in action. Annu Rev. Microbiol. 66, 493–520 (2012). · DOI · Paper page
  48. Bouteiller, M. et al. Pseudomonas flagella: Generalities and specificities. Int J Mol Sci. 22, https://doi.org/10.3390/ijms22073337 (2021). · DOI
  49. Pires, D. P. et al. A genotypic analysis of five P. aeruginosa strains after biofilm infection by phages targeting different cell surface receptors. Front Microbiol. 8, 1229 (2017). · DOI
  50. Kortright, K. E., Chan, B. K. & Turner, P. E. High-throughput discovery of phage receptors using transposon insertion sequencing of bacteria. Proc Natl Acad Sci. USA 117, 18670–18679 (2020). · DOI
  51. Siryaporn, A., Kim, M. K., Shen, Y., Stone, H. A. & Gitai, Z. Colonization, competition, and dispersal of pathogens in fluid flow networks. Curr. Biol. 25, 1201–1207 (2015). · DOI
  52. Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016). · DOI · Paper page
  53. Pan, X. et al. Genetic evidence for O-specific antigen as receptor of Pseudomonas aeruginosa phage K8 and Its genomic analysis. Front Microbiol. 7, 252 (2016). · DOI
  54. Ceyssens, P. J. et al. Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. Environ Microbiol. 11, 2874–2883 (2009). · DOI
  55. Davis, C. M., McCutcheon, J. G. & Dennis, J. J. Aztreonam lysine increases the activity of phages E79 and phiKZ against Pseudomonas aeruginosa PAO1. Microorganisms 9, https://doi.org/10.3390/microorganisms9010152 (2021). · DOI
  56. Kim, M. K. et al. Surface-attached molecules control Staphylococcus aureus quorum sensing and biofilm development. Nat Microbiol. 2, 17080 (2017). · DOI · Paper page
  57. Sweere, J. M. et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363, https://doi.org/10.1126/science.aat9691 (2019). · DOI · Paper page
  58. Chen, Q. et al. Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics. Pharmaceutics 14, https://doi.org/10.3390/pharmaceutics14071425 (2022). · DOI
  59. Estrella, L. A. et al. Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog(R) system. Bacteriophage 6, e1219440 (2016). · DOI
  60. Vandersteegen, K. et al. Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications. J Virol 87, 3237–3247 (2013). · DOI
  61. Takeuchi, I. et al. The Presence of Two Receptor-Binding Proteins Contributes to the Wide Host Range of Staphylococcal Twort-Like Phages. Appl. Environ. Microbiol. 82, 5763–5774 (2016). · doi:10.1128/aem.01385-16
  62. Chan, B. K. et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018, 60–66 (2018). · DOI · Paper page
  63. Arts, E. J. & Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2, a007161 (2012). · DOI · Paper page
  64. Schwarzer, D. et al. A multivalent adsorption apparatus explains the broad host range of phage phi92: a comprehensive genomic and structural analysis. J Virol 86, 10384–10398 (2012). · DOI
  65. Fungo, G. B. N. et al. Two Is Better Than One”: The Multifactorial Nature of Phage-Antibiotic Combinatorial Treatments Against ESKAPE-Induced Infections. Phage (New Rochelle) 4, 55–67 (2023).
  66. Pons, B. J., Dimitriu, T., Westra, E. R. & van Houte, S. Antibiotics that affect translation can antagonize phage infectivity by interfering with the deployment of counter-defenses. Proc Natl Acad Sci. USA 120, e2216084120 (2023). · DOI
  67. Yehl, K. et al. Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis. Cell 179, 459–469.e459 (2019). · DOI · Paper page
  68. Gomez-Ochoa, S. A. et al. Efficacy of phage therapy in preclinical models of bacterial infection: a systematic review and meta-analysis. Lancet Microbe 3, e956–e968 (2022). · DOI
  69. Visnapuu, A., Van der Gucht, M., Wagemans, J. & Lavigne, R. Deconstructing the Phage-Bacterial Biofilm Interaction as a Basis to Establish New Antibiofilm Strategies. Viruses 14, https://doi.org/10.3390/v14051057 (2022). · DOI
  70. Chen, Q. et al. Pf bacteriophages hinder sputum antibiotic diffusion via electrostatic binding. Sci. Adv. 10, eadl5576 (2024). · DOI
  71. Wang, I. N., Smith, D. L. & Young, R. Holins: the protein clocks of bacteriophage infections. Annu Rev. Microbiol. 54, 799–825 (2000). · DOI · Paper page
  72. Jakociune, D. & Moodley, A. A rapid bacteriophage DNA extraction method. Methods Protoc 1, https://doi.org/10.3390/mps1030027 (2018). · doi:10.3390/mps1030027
  73. Mukherjee, S. et al. The PqsE and RhlR proteins are an autoinducer synthase-receptor pair that control virulence and biofilm development in Pseudomonas aeruginosa. Proc Natl Acad Sci. USA 115, E9411–E9418 (2018). · DOI
  74. Lam, J. S., Anderson, E. M. & Hao, Y. LPS quantitation procedures. Methods Mol. Biol. 1149, 375–402 (2014). · DOI
  75. Kim, M. K., Ingremeau, F., Zhao, A., Bassler, B. L. & Stone, H. A. Local and global consequences of flow on bacterial quorum sensing. Nat. Microbiol. 1, 15005 (2016). · DOI · Paper page
  76. Hartmann, R. et al. Quantitative image analysis of microbial communities with BiofilmQ. Nat. Microbiol. 6, 151–156 (2021). · DOI · Paper page
  77. O’Toole, G. A. Microtiter dish biofilm formation assay. J Vis Exp https://doi.org/10.3791/2437 (2011). · DOI · Paper page
  78. Leclerc, Q. J., Lindsay, J. A. & Knight, G. M. Modelling the synergistic effect of bacteriophage and antibiotics on bacteria: Killers and drivers of resistance evolution. PLoS Comput Biol. 18, e1010746 (2022). · DOI

Cited by

See all 157

Metadata

Authors
Kim, M. K., Chen, Q., Echterhof, A., Pennetzdorfer, N., McBride, R. C., Banaei, N., Burgener, E. B., Milla, C. E., & Bollyky, P. L.
Venue
Nature Communications
Published
2024-11-28
Volume
15
Issue
1
ISSN
2041-1723
Cited by
157
References
2
Language
en
Licence
Funders
  • U.S. Department of Health & Human Services | National Institutes of Health (R01HL148184-01)
  • U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01AI12492093)
  • Cystic Fibrosis Foundation (CFF)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. https://app.cochat.ai/papers/10.1038/s41467-024-53994-9
The paper
Kim, M. K., Chen, Q., Echterhof, A., Pennetzdorfer, N., McBride, R. C., Banaei, N., Burgener, E. B., Milla, C. E., & Bollyky, P. L. (2024). A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nature Communications. https://doi.org/10.1038/s41467-024-53994-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.